[Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis].

药学学报 Pub Date : 2017-03-01
Fan Liu, Hao-yi Meng, Zheng-yang Sun, Dan-yang Li, Yuan-yuan Jin, Zhao-yong Yang, Shao-jie Wu, Jing Chen
{"title":"[Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis].","authors":"Fan Liu,&nbsp;Hao-yi Meng,&nbsp;Zheng-yang Sun,&nbsp;Dan-yang Li,&nbsp;Yuan-yuan Jin,&nbsp;Zhao-yong Yang,&nbsp;Shao-jie Wu,&nbsp;Jing Chen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains\nbecame a serious threat to public health. This status demands development of new antibacterial agents with\nnovel mechanisms of action. The reason for the limited new antibacterials is the small number of effective\ntherapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for\nnew targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component\nof the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical\npathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for\nthe development of new classes of antibacterial agents. This review provides an in-depth insight into the recent\ndevelopments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of\ncandidate inhibitors and the challenges to overcome the hurdles are also discussed.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"52 3","pages":"362-70"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains became a serious threat to public health. This status demands development of new antibacterial agents with novel mechanisms of action. The reason for the limited new antibacterials is the small number of effective therapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for new targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component of the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical pathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for the development of new classes of antibacterial agents. This review provides an in-depth insight into the recent developments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of candidate inhibitors and the challenges to overcome the hurdles are also discussed.

[细菌肽聚糖生物合成酶抑制剂的研究进展]。
近年来,由于抗生素的滥用,耐药菌株的广泛存在对公众健康构成了严重威胁。这一现状要求开发具有新的作用机制的新型抗菌药物。新型抗菌药物有限的原因是有效的治疗靶点较少,不能满足当前多重耐药治疗的需要。新靶点的筛选是开发新型抗菌药物的关键环节。肽聚糖是细菌细胞壁的主要成分,对致病菌的生存至关重要。在肽聚糖生物合成的生化途径中,murligase是开发新型抗菌剂的极具潜力的靶点。本文综述了近年来Mur酶抑制剂(MurA-F)的研究进展。此外,还讨论了候选抑制剂缺乏的原因和克服障碍所面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
药学学报
药学学报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍: Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信